Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
A 2:1:1 mixture of: trisodium N(1')-N(2):N(1''')-N(2'')-η-6-[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]-6''-(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'-azobenzene-1,2'-diolato-O(1),O(2'))-chromate; trisodium N(1')-N(2):N(1''')-N(2'')-η-6,6''-bis(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'azobenzene-1,2'-diolato-O(1),O(2'))-chromate; trisodium N(1')-N(2):N(1''')-N(2'')-η-6,6''-bis[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]5',5'''-disulfamoyl-3,3''-disulfonatobis(naphthalene-2,1'azobenzene-1,2'-diolato-O(1),O(2'))-chromate
EC number: 402-850-1 | CAS number: - NOIR SANDODERM HH 1050; SANDODERM BLACK HH 1050; SANDODERM BLACK R; SANDODERM BLACK R CONC.; SANDODERM SCHWARZ R; SANDODERM SCHWARZ R KONZ.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
LD50 (oral, rat) > 5000 mg/kg bw
LD50 (dermal, rat) > 2000 mg/kg bw
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
Acute oral toxicity
Acute oral toxicity of the substance was evaluated in an experimental study performed according to the OECD Guideline 401 (1987) and EU method B.1 (1984).
No mortality was observed at 2000 mg/kg bw, and 20 % mortality was observed at the higher dose of 5000 mg/kg bw. Toxic symptoms of sedation, dyspnoea, hunched posture and ruffled fur were observed in one male and one female animal administered 2000 mg/kg bw until day 4 and 5, respectively at 2000 mg/kg bw; toxic symptoms of sedation, dyspnoea, ataxia, hunched posture, diarrhoea and ruffled fur were observed in 1 - 2 male and 1 - 2 female animals until day 3 at 5000 mg/kg bw. Body weights of all animals remained constant. No gross pathological changes were observed among animals administered at 2000 mg/kg bw or the surviving animals administered at 5000 mg/kg bw; the two animals of the higher dose who died during the study period were found to have several dark red foci, partly black, of the lungs and black liver, stomach, intestines, kidneys, adrenal glands and spleen.
The LOGIT-Model could not be applied to these data. Based on these findings, the acute oral toxicity of the test item in rats of both sexes, observed over a period of 15 days, was estimated to be greater than 5000 mg/kg bw Therefore, it can be extrapolated that the LD50 is greater than 5000 mg/kg bw.
Acute inhalation toxicity
Study considered as scientifically not necessary: the study does not need to be conducted because exposure of humans via inhalation is not likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size
Acute dermal toxicity
Acute dermal toxicity of the test item was evaluated in an experimental study performed according to the OECD Guideline 402 (1987) and the EU Method B.3 (1984).
No mortality was observed. Local discolouration was observed after removal of the bandage (24 hours after application) until end of the observation period. Body weights of the animals remained constant. No pathological changes were observed at necropsy.
The LOGIT-Model could not be applied to these data. The acute dermal toxicity of the test item in rats of both sexes, observed over a period of 15 days, was estimated to be greater than 2000 mg/kg bw. Therefore, it can be extrapolated that the LD50 is greater than 2000 mg/kg bw.
Justification for classification or non-classification
According to the CLP criteria for acute toxicity (EC) No. 1272/2008, substances can be allocated to one of four hazard categories based on acute toxicity by the oral, dermal or inhalation route according to the numeric criteria shown in the table. Acute toxicity values are expressed as (approximate) LD50 (oral, dermal) or LC50 (inhalation) values or as acute toxicity estimates (ATE).
Acute toxicity hazard categories and acute toxicity estimates (ATE) are defined by the respective categories:
Danger | Danger | Danger | Warning | ||||
Unit | Category 1 | Category 2 | Category 3 | Category 4 | No Classification | ||
ORAL | mg/kg bw | LD50 ≤ 5 | 5 < LD50 ≤ 50 |
50< LD50 ≤ 300 | 300< LD50 ≤ 2000 | LD50> 2000 | |
DERMAL | mg/kg bw | LD50 ≤ 50 | 50< LD50 ≤ 200 | 200< LD50 ≤ 1000 | 1000< LD50 ≤ 2000 | LD50> 2000 |
According to the studies available, the test item cannot be classified as having an acute oral or dermal toxicity as the median lethal dose does not fulfill the abovementioned CLP criteria (LD50> 2000 mg/kg bw in both cases).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.